New Antibiotics Failing to Keep Pace with the Rise of Superbugs
The rise of drug-resistant superbugs has made the invention of new antibiotics an urgent need at the same time that their development is becoming uneconomical for pharmaceutical companies. This disparity is caused by a number of factors, including the the way in which hospitals are paid for treating infections, rules governing the use of antibiotics, and the small population who would benefit from these new treatments. The FDA is working incentivize investment in novel treatments of bacterial infections, but these efforts so far have not been adequate.
Full Story: STAT